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In silico peptide-directed ligand design
complements experimental peptide-directed
binding for protein–protein interaction modulator
discovery†
Lesley Ann Howell*a and Andrew Michael Beekman *b
Using the protein–protein interaction of Mcl-1/Noxa, two methods for efficient modulator discovery are directly
compared. In silico peptide-directed ligand design is evaluated against experimental peptide-directed binding,
allowing for the discovery of two new inhibitors of Mcl-1/Noxa with cellular activity. In silico peptide-directed
ligand design demonstrates an in vitro hit rate of 80% (IC50 o 100 mM). The two rapid and efficient methods
demonstrate complementary features for protein–protein interaction modulator discovery.
Introduction
Drug discovery for protein–protein interactions (PPIs) has made
huge advances in the last decade, making strides to shed the
‘‘undruggable’’ label. The application of fragment based drug
discovery1–3 and high throughput screening4,5 has resulted in
many compounds undergoing clinical trials,6–9 and the approval
of venetoclax in 2016.10 The methods have proven to be effective,
but remain available only to pharmaceutical companies and
specially equipped laboratories. In order to address this several
innovative techniques have been reported to streamline PPI
drug discovery.11 The development of constrained peptides12–15
and peptidomimetics,16–19 the application of new chemical
modalities,20–22 and the demonstration of dynamic ligation
screening23 has offered techniques for PPI modulation which
utilise the shrewd application of commonly available resources
and chemistries.
In an attempt to further improve the economy of drug discovery
for PPIs we recently reported peptide-directed binding24 as a
method to identify selective small molecule modulators. This
technique extends on the REPLACE technique,25–27 utilising
high affinity peptides as scaffolds for small molecule fragment
identification. Using the PPI of apoptosis influencing Mcl-1/
Noxa as a paradigm, we took the NoxaB-(75–93)-C75A peptide
(AAQLRRIGDKVNLRQKLLN, IC50 650 nM) and divided it into
two half peptides, amino acids 75–84 (AAQLRRIGD) and 85–93
(KVNLRQKLLN, Fig. 1: step 1), each containing two key binding
residues (L78, I81, V85, and Q89). Reactive terminals were
added to the termini of the half peptides, an alkyne on the C
terminus of AAQLRRIGD and an azide on the N terminus of
KVNLRQKLLN. These half peptides, with and without reactive
termini, possessed no discernible binding affinity for Mcl-1. The
reactive termini where used to ‘‘click’’ small molecule fragments
to the peptides, with copper catalysed alkyne azide cycloaddition.
The binding affinity of the peptide-small molecule hybrids was
examined. The fragments which were shown to restore binding
affinity in some way emulate the peptide segment they have
replaced (Fig. 1: step 2). The small molecule fragments that
appeared to emulate amino acids 75–84 where then clicked to the
small molecule fragments which emulated amino acids 85–93,
providing small molecules with a high probability of emulating
the entire NoxaB peptide (Fig. 1: step 3). The choice of small
molecule fragments to be clicked to peptides was guided by in silico
modelling of the covalent reaction, allowing for a high efficiency.
To further improve the efficiency of this method we applied
a fully computational peptide-directed ligand design to the PPIs
of hDM2/hDMX and p53.28 This process mirrored that of
peptide-directed binding, but performed steps 1–3 (Fig. 1)
computationally, identifying a number of small molecules triazoles
for synthesis. Analogous to our Mcl-1/Noxa example, the crystal
structures of a modified p53 peptide bound to both hDM2 and
hDMX were modified to generate two half peptides with reactive
azide and alkyne termini. In silico covalent docking was performed
to identify fragments which are likely to restore binding of the
semi-peptide. Here the two methods diverge. Instead of preparing
the identified peptide-small molecule hybrids, the top 10 azide
fragments and top 10 alkyne fragments were combined virtually to
identify 100 small molecule triazoles. This library was redocked to
the protein target and the top 10 results were chosen for synthesis.
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Our report of in silico peptide-directed ligand design28
demonstrated a higher efficiency at discovering small molecule
inhibitors of PPIs when compared to the analogous experimental
peptide-directed binding.24 The in silico method required the
preparation of only 20 compounds to obtain a 50% hit rate of
compounds which demonstrated an IC50 o 100 mM in in vitro
protein fluorescence anisotropy assays. The experimental method
revealed 54% of the small molecule compounds prepared
demonstrated an IC50 o 100 mM, slightly higher than the in
silico only route, but also required the preparation of 60 peptide-
small molecule hybrids, adding time and cost. The 60 hybrids
prepared identified 23 hits (reducing the hit rate to 44% for total
compounds synthesised), which suggested 104 possible small
molecule triazoles, of which we chose to prepare 35, based on
availability and cost of components. It may be by chance that our
hit rate was as high as observed, but seems unlikely given the
number of compounds observed. The question remained, is one
method clearly superior to the other, or are they complementary?
Results and discussion
To examine this, we performed in silico peptide-directed ligand
design on the Mcl-1/Noxa interaction, allowing for a direct
comparison of the experimental versus computational approach.
The crystal structure of Mcl-1/NoxaB (PDB ID 2NLA29) was modified
to generate the virtual reactive semi peptide AAQLRRIGD-
propargylglycine and covalent docking30,31 was used to model
copper catalysed azide alkyne cycloaddition in silico allowing us
to identify the top ten30 synthetically viable small molecule azides
fragments, from a commercially available library of 214 azides,
which fit into the site vacated by the other section of peptide.
Similarly, the crystal structure was modified to generate
a-azidoamide-KVNLRQKLLN, and covalent docking was performed
to identify small molecule alkyne fragments from a commercially
available library of 869 alkynes. To avoid bias the library was taken
directly from the Merck catalogue of available reagents. The top
10 azide and top 10 alkyne fragments were used to create a
virtual library of 100 triazoles which was docked to Mcl-1 in an
induced fit manner to score and rank the library. The library
was also evaluated to predict ADME properties (SwissADME
evaluation prediciting lipophilicity, water solubility, pharmaco-
kinetics, drug-likeness (Lipinski, Ghose, Veber) and PAINS and
lead-likeness screen),32 to help ensure synthetic effort was most
likely to generate results. The top 10 results were chosen for
synthesis following published procedures with CuSO4 and
sodium ascorbate in a tBuOH/H2O mix,
24 followed by purification
with reverse phase HPLC. Synthesised compounds were evaluated
in the FITC-NoxaB Mcl-1 competitive binding fluorescence
anisotropy (FA) assay (Table 1 and Fig. 2A).24
Fig. 1 Schematic of peptide directed binding. The process can be completed experimentally, with the preparation of small molecule–peptide hybrids,
identifying fragments which emulate half of the parent peptide. The identified small molecule fragments can be combined to create small molecules
which control the target PPI. The process can also be performed virtually, identifying likely small molecule triazole candidates for synthesis.
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The NoxaB peptide (AAQLRRIGDKVNLRQKLLN) was employed
as a positive control and to ensure the FA assay was performing
adequately. Surprisingly, of the ten compounds prepared eight
(80%) demonstrated binding in our assay, with an IC50 o 100 mM.
Additionally, three of these compounds (1–3) demonstrated IC50
values less than 1 mM Selectivity for the Mcl-1/Noxa was evaluated
by also examining the compounds in assays for Bcl-2/Bim, Bcl-xL/
Bim, and Nrf2/Keap1. The ten compounds demonstrated excellent
selectivity, with no appreciable inhibitory effect in these assays.
This very high hit rate demonstrates the power of peptide-
directed ligand design for PPI modulators. Analysis of the
compounds shows that four compounds were identified by
experimental peptide-directed binding (1, 2, 4 & 6),24 with four
new Mcl-1 binders identified with the in silico approach (3, 5, 7 & 8).
Three of the top four binders (1, 2 & 4) were identified by the
experimental peptide-directed binding, suggesting both experi-
mental and computational methods are likely to find the most
efficacious compounds. However, 1–6 have very similar structures,
with the Fmoc-D-propargylglycine unit cyclised with a benzyla-
zide, all of which demonstrated IC50 values o10 mM. The in
silico method highlighted four new small molecule fragments
which had not been highlighted in the experimental peptide-
directed binding methodology24 (azide section of 3, 7, 8, and the
alkyne section of 7 and 8). The binding of compounds to Mcl-1
was validated with a thermal shift assay33 using the hydrophobic
dye Sypro orange.34 Compound 1–8 demonstrated the ability to
increase the melting temperature of Mcl-1 compared to the
DMSO vehicle control (Fig. 2B).
The compounds which demonstrated activity in the in vitro
protein assays were evaluated in the MTS anti-proliferation
assay,35 against pancreatic cancer cells lines. BxPC3 cells, which
are dependent on Mcl-1, MiaPaCa2 cells, which are dependent
on Mcl-1 and Bcl-2, and AsPC-1 cells, which do not overexpress
Mcl-1,36–39 were treated with compound 1–8 (Table 2). Com-
pound 5–8 showed no antiproliferative effect in all evaluated cell
lines. Compound 1 and 2 demonstrated antiproliferative effects
on all evaluated cell lines. Interestingly, compound 3 and 4
demonstrated efficacies in BxPC3 and MiaPaCa-2 cells, but no
effect on Mcl-1 independent AsPC-1 cells, perhaps suggesting an
Mcl-1 selective mode of action. 3 and 4 also suggest a para
substituent of a certain size on the phenyl portion may offer
selectivity. Compound 9 and 10 were highlighted by the ADME
evaluation as unlikely to demonstrate cellular activity (c log P of
0.55 and 0.03 respectively), but were prepared nonetheless due to
their high docking ranking. These results suggest that the subse-
quent ADME evaluation will offer increased efficiency if heeded.
A tetramethylrhodamine ethyl ester (TMRE) assay was employed
to evaluate if compounds generated mitochondrial membrane
depolarization, one of the first signs of Mcl-1 inhibition
(Fig. 2C).40,41 BxPC-3 cells were incubated with compound 1–4 or
positive control, carbonyl cyanide 4-(trifluoromethoxy)phenyl-
hydrazone (FCCP), followed by TMRE. TMRE readily accumulates
in the mitochondria resulting in a fluorescent signal. Depolarized
mitochondria result in reduced fluorescence. Compound 1–4
showed significantly reduced fluorescence after 2 h of incubation,
indicating depolarized mitochondria membrane and apoptosis.
Table 1 IC50 values for the inhibition of the binding of FITC-NoxaB to Mcl-1 of small molecules
a
Structure FA IC50 (mM) Structure FA IC50 (mM)
1 0.17 [0.15–0.19] 6 3.38 [2.56–4.47]
2 0.36 [0.29–0.45] 7 4.39 [3.95–4.87]
3 0.62 [0.47–0.80] 8 7.03 [6.20–7.97]
4 1.01 [0.89–1.15] 9 4100
5 1.14 [0.84–1.52] 10 4100
a IC50 values determined by non-linear regression of at least three independent experiments (see ESI). Errors are 95% confidence intervals (CI).
Fmoc, 9-fluorenylmethylcarbonyl.
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Docking poses predicted by induced fit docking suggest
compounds are able to bind in the key P2 and P3 pockets.
Poses for compound 1 and 2 (Fig. 3), are representative of
binding poses generated for compound 1–8. The aromatic
groups create contacts with Phe270 in P2 and Phe228 in P3,
and interaction with Arg263 either through a water bridge
interaction or hydrogen bonding. In line with the design of
peptide-small molecule hybrids, the azide fragment which
interacts with Arg263 in the hybrids, also interacts with Arg263
in the predicted pose for compound 1. This motif is repeated in
the majority of the binding poses, but is not necessarily the
predicted lowest energy conformer. Voisin-Chiret and co-workers
recently highlighted the importance of the P2/P3 binding pockets
and Arg263 for binding of non-peptidic ligands.42 Representative
2D ligand interaction diagrams are presented in the ESI.†
Conclusion
This study has achieved a direct comparison of peptide-directed
binding and peptide-directed ligand design, using the Mcl-1/
Noxa PPI as a paradigm. Both techniques have demonstrated
50% or higher hit rates previously, but experimental peptide-
directed binding requires the synthesis of more molecules and
therefore higher cost. The computational design has been further
improved with the addition of ADME evaluation of highly ranked
compounds, and in this example 80% of the prepared com-
pounds demonstrated an IC50 o 100 mM in a fluorescence
anisotropy assay. This application of peptide-directed ligand
design to identify candidate triazoles is computationally
158 times more efficient than generating and screening a library
of possible triazoles. The approach described here screened
1210 compounds in an induced fit manner – 214 azides,
896 alkynes and 100 triazoles – whereas screening the same
fragment library as triazoles would have required the evaluation
of 191 744 compounds. The results demonstrated here suggest
that the techniques are complementary to each other. Both
techniques appear to identity hits with promising potency, and
both have identified compounds capable of demonstrating
desired effects in cellular assays. Experimental peptide-directed
binding has the advantage of identifying peptide-small molecule
hybrids, which in themselves present possible leads for develop-
ment. Computational peptide-directed ligand design allows for very
few compounds to be prepared while still identifying potent,
selective leads. While the experimental version requires more
compounds to be prepared, it does provide a greater structural
diversity, with computational methods highlighting one motif
many times. While chemists may prefer a wider array of structures
with which to learn from, biologists may prefer the limited
Fig. 2 (A) Fluorescence anisotropy titration of compound 1–10 on 5 nm
FITC-NoxaB peptide in the presence of 10 nm Mcl-1. (B) Thermal shift
assay of compound 1–8 showing the change in melting temperature (Tm)
of Mcl-1. (C) Mitochondrial depolarization assay of compound 1–4 and
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) demon-
strating the fluorescence change of TMRE.
Table 2 IC50 values for the cell growth inhibition of compounds which
demonstrated activity towards pancreatic cancer cell lines, demonstrated
by the MTS assaya
BxPC3 (mM) MiaPaCa-2 (mM) AsPC-1 (mM)
1 9.16 [5.97–14.88] 7.20 [6.15–8.45] 1.73 [1.42–2.14]
2 1.48 [1.20–1.87] 1.12 [1.36–1.94] 4.401 [3.86–5.02]
3 2.74 [1.56–5.00] 7.09 [5.50–9.09] 4100 mM
4 1.35 [1.23–1.49] 1.14 [1.10–1.19] 4100 mM
a IC50 values determined by non-linear regression of at least three
independent experiments (see ESI). Errors are 95% confidence intervals
(CI). Table 2: IC50 results obtained for compound 3 and 5 to selected
cancerous cell lines in the presence of jacalin or bovine serum albumin
(BSA) at 10 mM. Errors are 95% confidence intervals.
Fig. 3 Predicted binding poses of 1 (left) and 2 (right). Compounds bind in
the P2 and P3 pockets, making interactions with Phe228, Phe270 and
Arg263. Poses are representative of the lowest energy predicted poses.
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synthesis required to generate selective modulators. Both of these
techniques offer PPI researchers a rapid and efficient method to
generate selective modulators of a-helical PPIs.
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